How lidocaine gtt 2/2 drip help in migraine pain ?
Reading File
Lidocaine is a sodium channel blocker that, when given as a continuous IV infusion (gtt 2/2 typically means a 2 mg/mL solution at 2 mg/min), suppresses ectopic neuronal firing and dampens central sensitization - both of which are key mechanisms in refractory migraine pain.
Searching sources...
Finding Sources
Searching PubMed
lidocaine infusion migraine treatment
Reading File
Reading File
Searching PubMed
intravenous lidocaine migraine refractory
Reading Article
PMID: 34894295
Reading Article
PMID: 35609890
Finding Sources
Here is a detailed explanation of how a lidocaine 2% drip (gtt) helps in migraine pain:
Lidocaine Drip (2 mg/mL / 2 mg/min) in Migraine
What "Gtt 2/2" Means
"Gtt 2/2" in the clinical context typically refers to a continuous IV infusion of lidocaine at 2 mg/mL concentration running at 2 mg/min (or sometimes a weight-based protocol starting at 1-2 mg/kg). It is used in inpatient/hospital settings for refractory migraine - migraine that has not responded to standard therapies.
Mechanism of Action
Lidocaine is a Class IB sodium channel blocker. In migraine, it works through several interconnected mechanisms:
1. Sodium Channel Blockade - Core Mechanism
- Lidocaine blocks voltage-gated Na+ channels (specifically Nav1.1, Nav1.7, Nav1.8) on nociceptive trigeminal nerve fibers
- This suppresses ectopic neuronal firing and repetitive action potentials that propagate pain signals from the trigeminal nucleus caudalis to the cortex
- In migraine, trigeminal sensory fibers innervate intracranial blood vessels and meninges; lidocaine dampens their hyperexcitability
2. Inhibition of Central Sensitization
- Sustained migraine leads to central sensitization - a state of neuronal hyperexcitability in the trigeminal nucleus and thalamus
- IV lidocaine, by systemically reaching the CNS, reduces this central sensitization and helps "break the pain cycle"
- This is why it is particularly useful in status migrainosus or refractory chronic migraine
3. Suppression of Cortical Spreading Depression (CSD)
- CSD is a wave of neuronal and glial depolarization that propagates across the cortex and is believed to trigger migraine aura and headache
- Lidocaine, via Na+ channel blockade, can suppress CSD propagation, reducing both aura and the downstream activation of trigeminal pathways
4. Anti-inflammatory and Anti-nociceptive Effects
- At systemic levels, lidocaine inhibits neurogenic inflammation - the release of substance P, calcitonin gene-related peptide (CGRP), and other neuropeptides from trigeminal nerve terminals around meningeal vessels
- CGRP is the primary mediator of neurogenic vasodilation and pain in migraine; dampening its release is a key therapeutic target
5. Modulation of NMDA and AMPA Receptors
- Lidocaine also has some NMDA receptor antagonist activity, contributing to its anti-sensitization effect in the dorsal horn and trigeminal nucleus
Clinical Use Protocol
| Parameter | Detail |
|---|---|
| Setting | Inpatient / monitored infusion unit |
| Indication | Refractory migraine, status migrainosus, refractory chronic migraine |
| Dose | IV 1-2 mg/kg loading, then continuous infusion 1-3 mg/min (titrated) |
| Duration | Typically 3-7 days in hospital ("multiday infusion") |
| Monitoring | Continuous cardiac monitoring (ECG), BP, plasma lidocaine levels |
| Adjuncts | Often combined with ketorolac, magnesium, dihydroergotamine (DHE), methylprednisolone, neuroleptics |
A rapid one-time abortive dose is 100 mg IV bolus (as listed in Morgan & Mikhail's Clinical Anesthesiology) for acute migraine.
Evidence Base
A large retrospective analysis of 609 hospital admissions (Schwenk et al., Reg Anesth Pain Med 2022) found:
- Median pain score dropped from 7.0 to 1.0 by end of hospitalization (p<0.001)
- 87.8% of patients were acute responders
- 43% remained sustained responders at 1 month
- Nausea/vomiting were the most common (mild) side effects
A 2021 review by Mojica et al. in Current Pain and Headache Reports (PMID: 34894295) confirms that in carefully monitored inpatient settings, IV lidocaine and ketamine infusions are increasingly used when the standard Raskin protocol (DHE + antiemetic) fails.
From Tintinalli's Emergency Medicine: "A small number of studies using IV lidocaine (50-150 mg or 1-2 mg/kg) for ED migraine management show no consistent benefit vs. standard therapy (morphine, ketorolac, DHE, chlorpromazine)" - so in the ED setting, lidocaine is not considered first-line.
Important Caveats
- Not a first-line treatment - reserved for refractory cases after triptans, DHE, antiemetics, and NSAIDs have failed
- Requires continuous cardiac monitoring - risk of arrhythmias, hypotension, CNS toxicity (tinnitus, perioral numbness, seizures at toxic levels)
- Plasma lidocaine levels should be checked during multiday infusions (therapeutic range 1.5-5 mcg/mL; toxicity >5 mcg/mL)
- Evidence is mostly from retrospective studies; prospective RCTs are still needed
In summary: Lidocaine drip in migraine works primarily by blocking Na+ channels on trigeminal nociceptive fibers, suppressing central sensitization, inhibiting CGRP-mediated neurogenic inflammation, and possibly suppressing cortical spreading depression - collectively "breaking" the sustained pain cycle in refractory migraine. - Morgan & Mikhail's Clinical Anesthesiology, p. 2023; Tintinalli's Emergency Medicine, p. 3425
This is a shared conversation. Sign in to Orris to start your own chat.